- Home
- ELBM vs BCAB Comparison
ELBM vs BCAB Comparison
Compare ELBM & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELBM
- BCAB
- Stock Information
- Founded
- ELBM 2011
- BCAB 2007
- Country
- ELBM Canada
- BCAB United States
- Employees
- ELBM N/A
- BCAB N/A
- Industry
- ELBM Industrial Machinery/Components
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- ELBM Miscellaneous
- BCAB Health Care
- Exchange
- ELBM Nasdaq
- BCAB Nasdaq
- Market Cap
- ELBM 25.0M
- BCAB 28.6M
- IPO Year
- ELBM N/A
- BCAB 2020
- Fundamental
- Price
- ELBM $1.57
- BCAB $0.47
- Analyst Decision
- ELBM Strong Buy
- BCAB Buy
- Analyst Count
- ELBM 1
- BCAB 2
- Target Price
- ELBM $5.20
- BCAB $5.00
- AVG Volume (30 Days)
- ELBM 40.6K
- BCAB 990.6K
- Earning Date
- ELBM 11-15-2024
- BCAB 03-25-2025
- Dividend Yield
- ELBM N/A
- BCAB N/A
- EPS Growth
- ELBM N/A
- BCAB N/A
- EPS
- ELBM N/A
- BCAB N/A
- Revenue
- ELBM N/A
- BCAB $11,000,000.00
- Revenue This Year
- ELBM N/A
- BCAB N/A
- Revenue Next Year
- ELBM $1,630.56
- BCAB N/A
- P/E Ratio
- ELBM N/A
- BCAB N/A
- Revenue Growth
- ELBM N/A
- BCAB N/A
- 52 Week Low
- ELBM $1.04
- BCAB $0.43
- 52 Week High
- ELBM $3.00
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- ELBM 40.60
- BCAB 23.28
- Support Level
- ELBM $1.35
- BCAB $0.46
- Resistance Level
- ELBM $1.55
- BCAB $0.49
- Average True Range (ATR)
- ELBM 0.08
- BCAB 0.04
- MACD
- ELBM 0.00
- BCAB 0.03
- Stochastic Oscillator
- ELBM 32.35
- BCAB 27.98
About ELBM Electra Battery Materials Corporation
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.